Treating acute leukaemias of ambiguous lineage

Bookmark and Share
Published: 8 Dec 2020
Views: 114
Dr Lindsey Montefiori - Department of Pathology, St. Jude Children's Research Hospital, USA

Dr Lindsey Montefiori speaks to ecancer about a study recently presented at ASH 2020; ‘Enhancer hijacking of BCL11B defines a subtype of lineage ambiguous acute leukaemia.’

She first talks about the rationale behind the study saying acute leukaemias of ambiguous lineage (ALAL), including those that express combinations of myeloid, T-lineage and stem cell markers such as T/myeloid mixed phenotype acute leukaemia (MPAL) and early T cell precursor acute lymphoblastic leukaemia (ETP-ALL), remain challenging to diagnose, classify and treat.

She says the aim of the study was to define the genomic basis of these leukaemias, and thus, a large pan-acute leukaemia analysis was carried out.

Dr Montefiori then describes the methodology used in this and then moves on to explain the key results. She further talks about the results from the chromatin topology analysis and talks about the future of this research.

This program is funded in part via an independent grant from AbbVie. ecancer is editorially independent and there is no influence over content.